Pancreatic cancer
Conditions
Brief summary
Progression free survival based on the RECIST-criteria
Detailed description
Key secondary efficacy endpoint: Overall survival., Time to treatment failure, defined as time from study day 1 to disease progression (RECIST-criteria from CT) and/or rapidly deteriorating ECOG performance status., Number of completed chemotherapy cycles before treatment failure, Changes in local disease progression using RECIST-criteria (CT), Changes in maximum tumour diameter (CT and ultrasound), Changes in disease progression using primary tumour volume (CT and ultrasound)
Interventions
DRUGdispersjon
DRUGIrinotecan Accord 20 mg/ml konsentrat til infusjonsvæske
DRUGoppløsning
DRUGGemkabi 38 mg/ml konsentrat til infusjonsvæske
DRUGAbraxane 5 mg/ml powder for dispersion for infusion.
DRUGOksaliplatin SUN 5 mg/ml konsentrat til infusjonsvæske
Sponsors
Helse Bergen HF
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival based on the RECIST-criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| Key secondary efficacy endpoint: Overall survival., Time to treatment failure, defined as time from study day 1 to disease progression (RECIST-criteria from CT) and/or rapidly deteriorating ECOG performance status., Number of completed chemotherapy cycles before treatment failure, Changes in local disease progression using RECIST-criteria (CT), Changes in maximum tumour diameter (CT and ultrasound), Changes in disease progression using primary tumour volume (CT and ultrasound) | — |
Countries
Norway
Outcome results
None listed